Loading…

Merck KGaAMRK.DECompetitor analysis, valuation and peers

Germany · EUR·Health Care›Pharmaceuticals: Major

German science and technology company selling life-science lab tools (MilliporeSigma), specialty pharmaceuticals and electronic materials for chipmaking.

≈ Owns MilliporeSigma; unrelated to US-listed Merck & CoMomentum leader 82
Mkt cap
$71.3B
US dollars, full cap
Free float
97%
of shares outstanding
$/day
$48.4M
20-day average traded
Fwd P/E
17.4×
forward earnings
ROIC−WACC
+0.6 pp
WACC 6.7%
Hurdle
+4 pp
Req g minus delivered
Official | Implied
A / AA+
agencies · bond market
Next earnings
106 days
4 Mar 2027
Close · EUR€149.50
1D-0.8%
1W-1.4%
1M+2.1%
3M+8.4%
6M+16.5%
YTD+21.9%
1Y+35.1%
ATR %2.2%
52w lowhigh4.3% off high

What Merck KGaA does

German science and technology company selling life-science lab tools (MilliporeSigma), specialty pharmaceuticals and electronic materials for chipmaking.

Life Science, selling lab supplies and the filters and media drugmakers need to make biologic drugs, is the biggest part, with recurring consumables rather than machines. Healthcare and electronic materials are the other two. The Merck family keeps control through a holding company. It bought Sigma-Aldrich in 2015 and Versum Materials in 2019.

In one line: Owns MilliporeSigma; unrelated to US-listed Merck & Co.

Products and services

  • Life Science (MilliporeSigma lab tools/bioprocessing)
  • Healthcare (oncology, fertility drugs)
  • Electronics (semiconductor materials, display materials)

Customers

  • Pharma/biotech companies (lab tools)
  • Hospitals/physicians (drugs)
  • Semiconductor/display manufacturers

Where it sits in the supply chain

  • Life sciences/pharma/materials
  • Diversified science conglomerate
  • Lab tools & bioprocessing…

What could go right

  • Biopharma bioprocessing demand
  • Semiconductor materials growth (AI chips)
  • Life science tools recovery

What could go wrong

  • Biotech funding cycle affecting lab tool sales
  • Semiconductor cycle exposure
  • Drug patent expirations

Moat: narrow (switching costs, IP / patents, customer qualification). Lab reagents/bioprocessing tools are validated into customer workflows, and electronic materials require fab qualification.

Headquarters: Darmstadt, Germany · Founded: 1668 · Employees: 62,461

Named competitors

Merck KGaA at a glance

Size Merck KGaA (MRK.DE) is a Germany Health Care company (Pharmaceuticals: Major) with a market value of $71.3B, the 8th largest of 198 Germany companies the cockpit tracks. Shares closed at €149.50 on 18 Nov 2026.

Performance Over six months the shares gained 16.5%, against +11.2% for the median peer and -0.9% for the Germany market (cap-weighted) — 10th highest of 21 in its peer set.

Growth Revenue grew 0.8% over the last twelve months (peer median +8.6%); the operating margin is 19.4% (peer median 25.3%).

Valuation It trades at 17.4× forward earnings against a peer median of 16.9× (9th most expensive of 21).

Price implies For today's price to make sense, revenue must grow about 7% a year for seven years (Req g). Recent delivered growth is +4%, so the hurdle is +4 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 0.6 points above its cost of capital (6.7% WACC).

Credit Merck KGaA has 10 bonds outstanding ($7.08B), rated A by the agencies and trading like AA+ at a weighted spread of 67 bp.

Next results Next results expected around 4 Mar 2027 (exchange calendar; dates can move).

Relative performance

10011021 May 202621 Aug 202618 Nov 2026MRK.DE 115Peer median 113
Six months, rebased to 100: Merck KGaA against the median of its 20 peers (local-currency closes).

Merck KGaA financials

Reported figures in EUR; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue€21.4B€21.1B€21.2B€21.0B€22.2B
Revenue growth—0%+1%-6%—
Gross profit€12.6B€11.9B€11.9B€11.7B€12.8B
EBITDA€7.10B€5.95B€6.17B€5.83B€6.79B
Net income€1.92B€2.61B€2.78B€2.82B€3.33B
Free cash flow€3.00B€2.35B€2.88B€1.98B€2.73B
Capital expenditure€3.67B€3.56B€4.43B€4.52B€2.88B
Total debt€12.0B€12.0B€10.3B€9.94B€10.4B

Quarterly statements and history in the cockpit →

Merck KGaA competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+20%+40%0%+10%45024519603259BAYNREGNGSKGALDSUNPHARMA600276688235SANBMYSDZ4578HLNRPRXVRTXBIIBZTSPFEMRK.DE6-month return →1-month return →
Up and to the right = strong over both horizons. Merck KGaA is the large dot.

Fundamentals: revenue growth against valuation

0%+10%+20%20×40×45024519603259BAYNREGNGSKGALDSUNPHARMA600276688235SANBMYSDZ4578HLNRPRXVRTXZTSPFEMRK.DERevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Merck KGaA is the large dot.

Capital: growth delivered against growth the price implies

0%+25%+50%+75%0%50%45024519603259REGNGSKGALDSUNPHARMA600276688235SANBMYSDZMRK.DEGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Merck KGaA is the large dot.

Merck KGaA competitors and peer comparison

Head to head with its named competitors (MRK.DE vs TMO vs DHR vs BAYN.DE)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Merck KGaA MRK.DE$71.3B+16%+1%19%17.4×7.4%
Thermo Fisher Scientific TMO$257B+53%+8%19%25.7×21.3%
Danaher DHR$161B+34%+6%21%25.1×20.8%
Bayer BAYN.DE$60.3B+48%0%13%12.3×n/a
Shin-etsu Chemical 4063.T$67.9B-22%+5%25%17.7×9.9%
Sartorius SRT.DE$19.9B+26%+4%18%43.0×25.6%

How Merck KGaA compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Merck KGaA against its 20 peers (data as of 18 Nov 2026)
MeasureMRK.DEPeer medianRank in peer set
1-month return+2.1%+5.0%8th lowest of 21
6-month return+16.5%+11.2%10th highest of 21
Distance from 52-week high-4.3%-7.4%6th highest of 21
Revenue growth (TTM)+0.8%+8.6%3rd lowest of 21
Operating margin19.4%25.3%8th lowest of 21
Forward P/E17.4×16.9×9th most expensive of 21
Growth the price implies (Req g, 7 yrs)7.4%5.2%8th most demanding of 20
Growth delivered (Del g)+3.8%+7.1%8th lowest of 20
Hurdle (Req g minus delivered)+3.7 pp-4.8 pp7th most demanding of 20
ROIC minus cost of capital+0.6 pp+4.8 pp5th lowest of 21
EV / EBITDA10.4×13.8×8th cheapest of 19
Net debt / EBITDA1.2×1.8×8th least indebted of 19
Bond spread67 bp84 bp2nd tightest of 14

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Merck KGaA MRK.DEGermany$71.3B+16%+1%19%17.4×7.4%+3.8%
Takeda Pharmaceutical 4502.TJapan$69.8B+30%+6%18%51.0×3.7%+7.1%
Chugai Pharmaceutical 4519.TJapan$75.2B-8%+17%50%23.7×5.0%+9.8%
WuXi AppTec 603259.SSChina$64.2B+40%+32%43%17.0×7.2%+22.3%
Bayer BAYN.DEGermany$60.3B+48%0%13%12.3×n/an/a
Regeneron Pharmaceuticals REGNUnited States$97.8B+46%+19%30%11.8×-1.1%+11.0%
GSK GSK.LUnited Kingdom$97.9B-3%+4%25%10.4×-0.1%-0.9%
Galderma GALD.SWSwitzerland$51.9B+18%+16%19%45.7×18.0%+6.4%
Sun Pharmaceutical Industries SUNPHARMA.NSIndia$48.0B-1%+12%23%36.0×28.7%+11.7%
Jiangsu Hengrui Pharmaceuticals 600276.SSChina$45.7B-13%+6%27%33.4×13.4%+2.7%
BeOne Medicines 688235.SSChina$45.5B+9%+25%18%59.7×19.1%+79.3%
Sanofi SAN.PAFrance$114B+13%+15%27%9.7×-4.8%+3.9%
Bristol Myers Squibb BMYUnited States$122B+3%+4%33%9.2×-13.1%+2.5%
Sandoz SDZ.SWSwitzerland$41.7B+26%+1%15%24.5×7.5%+0.4%
Otsuka Hldgs 4578.TJapan$39.9B+9%+11%18%16.8×1.6%+11.7%
Haleon HLN.LUnited Kingdom$39.6B0%+1%23%16.4×5.2%+2.2%
Royalty Pharma RPRXUnited States$39.4B+29%+11%66%11.5×10.8%+2.3%
Vertex Pharmaceuticals VRTXUnited States$136B+25%+11%35%28.5×6.2%+14.2%
Biogen BIIBUnited States$37.2B+34%+2%17%17.1×10.1%-5.1%
Zoetis ZTSUnited States$34.8B+7%+1%37%13.8×-2.9%+7.2%
Pfizer PFEUnited States$160B+9%+1%26%9.9×-4.3%+8.5%

Merck KGaA bonds and credit

Merck KGaA has 10 bonds outstanding with $7.08B face value. The agencies rate it A; its bonds trade like AA+. Weighted yield 4.07%, a spread of 67 bp over government bonds.

Every bond, yield and spread in the cockpit →

Questions

Who are Merck KGaA's main competitors?
Named competitors: Thermo Fisher Scientific (TMO), Danaher Corp (DHR), Bayer (healthcare) (BAYN.DE), Shin-Etsu Chemical (4063.T), Sartorius AG (SRT.DE). The cockpit's measured peer set (industry) also includes Takeda Pharmaceutical (4502.T), Chugai Pharmaceutical (4519.T), WuXi AppTec (603259.SS), Bayer (BAYN.DE), Regeneron Pharmaceuticals (REGN), GSK (GSK.L).
Is Merck KGaA expensive compared with its peers?
On forward p/e it trades at 17.4× against a peer median of 16.9×, 9th most expensive of 21 in its peer set. For today's price to make sense, revenue must grow about 7% a year for seven years (Req g). Recent delivered growth is +4%, so the hurdle is +4 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Merck KGaA stock performed?
Over six months to 18 Nov 2026 the shares returned +16.5% against +11.2% for the median peer; over one year +35.1%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.